Skip to site menu Skip to page content

Login

Menu

Search

Sections

Home
News
Analysis
Pharma
Themes
Insights
Companies
Webinar & Events
Buy Reports
Excellence Awards
Innovation Rankings
Magazine
Newsletters

GlobalData

About us
Advertise With Us
Contact Us
Our Marketing Solutions
GlobalData Reports
Visit GlobalData

From Our Partners

Biopharma Playbooks: Solutions at the Speed of Science
Control and confidence in clinical data management
Accelerating Biopharmaceutical Innovation
Precision medicine and digital health innovation for disease diagnosis, care and treatment
The next chapter of clinical trial services
Putting quality first in the pharma supply chain
Maximising molecule potential

News
Analysis
Sections
Latest
Pharma
Sections
Latest
Themes
Sections
Latest
Insights
Sections
Latest
Companies
Sections
Latest
Webinar & Events
Sections
Latest
Buy Reports
Newsletters

Analysis

Left

Right

Features
Comment & Opinion
Projects
Data Insights

Data Insights

Filter search results

By Company Name

No filters selected

By Disease Name

No filters selected

By Drug Name

No filters selected

By Themes

No filters selected

Showing 2 results out of 2

Industry Themes and Signals

Decode the future of Pharmaceuticals. Access unrivalled intelligence on new technologies, macroeconomic shifts and social trends.

Get the insights you need to stay one step ahead - from smart cities to artificial intelligence, from nanomedicine to de-globalization.
Or go granular and access the latest signals on deals, filings, patents, hiring activities and more!

Data Insights

(Daratumumab + hyaluronidase (human recombinant)) by Johnson & Johnson for Peripheral Neuropathy (Sensory Neuropathy): Likelihood of Approval

(Daratumumab + hyaluronidase (human recombinant)) is under clinical development by Johnson & Johnson and currently in Phase II for Peripheral...

Likelihood of Approval and Phase Transition Success Rate Model - (Daratumumab + Hyaluronidase (human Recombinant)) in Peripheral Neuropathy (Sensory Neuropathy)

Data Insights

(Daratumumab + hyaluronidase (human recombinant)) by Johnson & Johnson for Alzheimer's Disease: Likelihood of Approval

(Daratumumab + hyaluronidase (human recombinant)) is under clinical development by Johnson & Johnson and currently in Phase II for Alzheimer's...

Likelihood of Approval and Phase Transition Success Rate Model - (Daratumumab + Hyaluronidase (human Recombinant)) in Alzheimer's Disease

The leading site for news and procurement in the pharmaceutical industry

About us
Advertise with us
License our content
Contact us
Editorial approach
Newsletters
Our marketing solutions

Privacy policy
Terms and conditions
Sitemap

Powered by

© GlobalData Plc 2026

Lost Password Back ⟶
Login
Register

Lost Password?

Registration is disabled.